<PAGE> 1
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
FILED BY THE REGISTRANT /X/ FILED BY A PARTY OTHER THAN THE REGISTRANT / /
- --------------------------------------------------------------------------------
Check the appropriate box:
/ / Preliminary Proxy Statement
/X/ Definitive Proxy Statement
/ / Definitive Additional Materials
/ / Soliciting Material Pursuant to sec.240.14a-11(c) or sec.240.14a-12
/ / Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
PRECISION OPTICS CORPORATION, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
/ / $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), or 14a-6(i)(2) or
Item 22(a)(2) of Schedule 14A.
/ / $500 per each party to the controversy pursuant to Exchange Act Rule
14a-6(i)(3).
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act
Rule 0-11 (Set forth the amount on which the filing fee is calculated and
state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
2) Form, Schedule or Registration Statement No.:
3) Filing Party:
4) Date Filed:
- --------------------------------------------------------------------------------
<PAGE> 2
PRECISION OPTICS CORPORATION, INC.
22 EAST BROADWAY
GARDNER, MASSACHUSETTS 01440
October 11, 1996
To the Shareholders:
The Board of Directors and Officers of Precision Optics Corporation, Inc.
invite you to attend the 1996 Annual Meeting of Shareholders to be held Tuesday,
November 12, 1996, at 10:00 a.m. at the Westminster Village Inn, Village Inn
Road, Westminster, Massachusetts.
A copy of the Proxy Statement and the Company's 1996 Annual Report to
Shareholders are enclosed.
If you cannot be present at the meeting, please mark, date, and sign the
enclosed proxy and return it as soon as possible in the enclosed envelope.
Very truly yours,
RICHARD E. FORKEY
President
<PAGE> 3
PRECISION OPTICS CORPORATION, INC.
22 EAST BROADWAY
GARDNER, MASSACHUSETTS 01440
NOTICE OF 1996 ANNUAL MEETING OF SHAREHOLDERS
NOVEMBER 12, 1996
The 1996 Annual Meeting of Shareholders of Precision Optics Corporation,
Inc. will be held on Tuesday, November 12, 1996, at 10:00 a.m. at the
Westminster Village Inn, Village Inn Road, Westminster, Massachusetts, for the
following purposes:
1. To elect one director to hold office for a three-year term and until
his successor shall be elected and shall have been qualified; and
2. To transact any and all other business that may properly come before
the meeting or any adjournment thereof.
All shareholders of record at the close of business on Monday, September
30, 1996, are entitled to notice of and to vote at the meeting.
Shareholders are requested to sign and date the enclosed proxy and return
it in the enclosed envelope. The envelope requires no postage if mailed in the
United States.
By Order of the Board of Directors,
EDWARD A. BENJAMIN
Clerk
October 11, 1996
<PAGE> 4
PRECISION OPTICS CORPORATION, INC.
PROXY STATEMENT
---------------
INFORMATION CONCERNING SOLICITATION AND VOTING
GENERAL
This Proxy Statement and form of proxy are furnished in connection with the
solicitation of proxies by the Board of Directors of Precision Optics
Corporation, Inc., a Massachusetts corporation (the "Company"), for the 1996
annual meeting of shareholders of the Company to be held November 12, 1996, at
10:00 a.m. and any adjournments thereof, for the purposes set forth in the
notice of meeting. The Company was incorporated in 1982, and its principal
executive offices are at 22 East Broadway, Gardner, Massachusetts 01440
(telephone 508-630-1800). This Proxy Statement and form of proxy are first being
distributed to shareholders on or about October 11, 1996.
VOTING RIGHTS AND OUTSTANDING SHARES
As of September 30, 1996, the Company had outstanding 5,980,502 shares of
Common Stock, $0.01 par value (the "Common Stock"). Each share of Common Stock
entitles the holder of record thereof at the close of business on September 30,
1996 to one vote in person or by proxy on the matters to be voted upon at the
meeting.
The Company will bear all the costs of the solicitation of proxies. The
Board of Directors may arrange with brokerage houses and other custodians,
nominees, and fiduciaries to forward solicitation materials to the beneficial
owners of the stock held of record by such persons, and the Company may
reimburse them for the reasonable out-of-pocket expenses incurred in so doing.
In addition to the solicitation of proxies by use of the mails, the Company may
use the services of some of its directors, officers, and regular employees (who
will receive no compensation therefor in addition to their regular salaries) to
solicit proxies personally or by mail or telephone.
Consistent with Massachusetts law and under the Company's by-laws, the vote
of a majority of the shares entitled to be cast on a particular matter, present
in person or represented by proxy, constitutes a quorum as to such matter. Votes
cast by proxy or in person at the Annual Meeting will be counted by persons
appointed by the Company to act as election inspectors for the meeting.
If the enclosed form of proxy is properly signed and returned and not
revoked, the shares represented thereby will be voted at the Annual Meeting. If
the shareholder specifies in the proxy how the shares are to be voted, they will
be voted as specified. If the shareholder does not specify how the shares are to
be voted, such shares will be voted to elect the nominee for director. Shares
represented by proxies that withhold authority to vote for the nominee for
election as a director or indicate an abstention or a "broker non-vote" (that
is, shares represented at the Meeting held by brokers or nominees as to which
(i) instructions have not been received from the beneficial owners or persons
entitled to vote and (ii) the broker or nominee does not have the discretionary
voting power on a particular matter) will be counted as shares that are present
and entitled to vote on the matter for purposes of determining the presence of a
quorum. Such shares, however, will not constitute votes cast at the meeting and
thus will have no effect on the outcome. The election of director described
below requires a plurality of votes cast. Should the person so named as nominee
be unable or unwilling to serve as director, the persons named in the form of
proxy for the annual meeting may, in their discretion, vote for such other
person or may vote to fix the number of directors at such number less than four,
<PAGE> 5
as the Board of Directors may recommend. Any shareholder has the right to revoke
his or her proxy at any time before it is voted by attending the meeting and
voting in person or by filing with the Clerk of the Company a written instrument
revoking the proxy or another newly executed proxy bearing a later date.
At the date hereof, the Company's management has no knowledge of any
business other than that described in the notice for the annual meeting which
will be presented for consideration at such meeting. If any other business
should come before such meeting, the persons appointed by the enclosed form of
proxy may, in their discretion, vote all such proxies, as the Board of Directors
may recommend. The persons appointed by the enclosed form of proxy also may, in
their discretion, vote all proxies with respect to matters incident to the
conduct of the meeting.
ITEM 1. ELECTION OF DIRECTORS
<TABLE>
The Company's Board of Directors is divided into three classes, as nearly
equal in number as reasonably possible, with staggered terms of office. Only one
class is elected each year, and each director serves a three year term and until
his or her successor has been duly elected and qualified. The Board of Directors
has fixed the number of directors at four. At the annual meeting it is intended
that the Company's Class III Director (Mr. Shannon) be elected to hold office
until the annual meeting of shareholders in 1999 and until his respective
successors have been duly elected and qualified. The nominee is currently a
director of the Company. The directors in Class I (Messrs. Forkey and Benjamin)
will hold office until the annual meeting of shareholders in 1997, and the
director in Class II (Mr. Pitlor) will hold office until the annual meeting of
shareholders in 1998 (and in each case, until their successors have been duly
elected and qualified). The names, ages, principal occupations for at least the
last five years, and certain other information with regard to the directors,
including the nominees, are as follows:
<CAPTION>
NAME AND YEAR PRINCIPAL OCCUPATION; DIRECTORSHIPS
FIRST ELECTED DIRECTOR AGE OF OTHER PUBLIC COMPANIES
---------------------- --- ---------------------------------------------------
<S> <C> <C>
Richard E. Forkey (1982)*.......... 56 President, Treasurer, and a director of the Company
since founding the Company in 1982; Clerk of the
Company from May 1983 to June 1990.
Edward A. Benjamin (1990)*......... 58 Clerk and a director of the Company since June
1990. Mr. Benjamin has been a partner in the law
firm of Ropes & Gray, Boston, Massachusetts, since
1969.
Joel R. Pitlor (1990)*............. 57 Since 1979, president of J.R. Pitlor, a management
consulting firm that provides strategic business
planning, which Mr. Pitlor founded. Mr. Pitlor has
provided business planning consultation to the
Company since 1983. Mr. Pitlor has been a director
of Bioplasty, Inc., a Minnesota-based medical
products supplier, since 1988 Mr. Pitlor has been a
director of the Company since June 1990.
Robert R. Shannon (1990)........... 64 Since 1969, professor at the Optical Sciences
Center of the University of Arizona and Director of
the Center from 1983 to July 1992. Mr. Shannon has
been a director of the Company since June 1990.
- ---------------
<FN>
* Directors whose terms do not expire this year.
</TABLE>
2
<PAGE> 6
All of the shareholders holding shares of the Company's Common Stock are
entitled to cast one vote in person or by proxy for each share standing in their
names and are entitled to elect one director at the 1996 annual meeting. If the
nominees are not available as candidates when the election occurs, the persons
named in the proxy may, within their discretion, vote for the election of such
other persons as the Board of Directors may designate or to reduce the number of
directors correspondingly. The Company has no reason to believe that the
nominees will not be available for election.
BOARD OF DIRECTORS
During the fiscal year ended June 30, 1996, the Company's Board of
Directors held three meetings. The Option Committee of the Board of Directors
acted by unanimous consent on three occasions during the fiscal year ended June
30, 1996.
Information as to ownership of the Company's securities by the nominee for
director is included under the heading "Security Ownership of Certain Beneficial
Owners and Management."
EXECUTIVE OFFICERS
<TABLE>
The Company's executive officers as of June 30, 1996 were as follows:
<CAPTION>
NAME AGE POSITION
---- --- --------
<S> <C> <C>
Richard E. Forkey........... 56 President, Treasurer
Jack P. Dreimiller.......... 48 Senior Vice President, Finance, and Chief Financial
Officer
Robert C. Meinhold.......... 41 Vice President, Sales and Marketing
</TABLE>
Mr. Forkey has been the President, the Treasurer, and a director of the
Company since he founded the Company in 1982. He was the Clerk of the Company
from May 1983 to June 1990.
Mr. Dreimiller has been Senior Vice President, Finance and Chief Financial
Officer since April 1992. From 1986 to 1991, he was Vice President, Finance at
Xerox Imaging Systems, Inc., a wholly-owned subsidiary of Xerox Corporation and
manufacturer of optical scanning systems and reading machines for the blind.
Mr. Meinhold has been Vice President, Sales and Marketing since January
1994. From November 1992 to January 1994, he was Director, Sales and Marketing
of the Company. From January 1991 to November 1992, he was Director of Marketing
at Davis and Geck, a division of American Cyanamid Corporation and manufacturer
of surgical devices. From 1989 to 1990, Mr. Meinhold was National Sales Manager
of the Patient Care Division of C.R. Bard, a manufacturer of medical and
surgical equipment.
3
<PAGE> 7
COMPENSATION AND OTHER MATERIAL TRANSACTIONS
EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE
<TABLE>
The following table sets forth all compensation for the last three
completed fiscal years awarded to, earned by, or paid to the Company's Chief
Executive Officer at June 30, 1996 and most highly paid executive officers who
served as executive officers at June 30, 1996 whose total annual salary and
bonuses for the fiscal year ended June 30, 1996 exceeded $100,000 for all
services rendered in all capacities to the Company and its subsidiaries (the
"Named Executive Officers").
SUMMARY COMPENSATION TABLE
<CAPTION>
LONG TERM
COMPENSATION
AWARDS
------------
ANNUAL COMPENSATION SECURITIES
------------------------------------------------------ UNDERLYING
NAME AND PRINCIPAL POSITION OTHER ANNUAL OPTIONS
AT FISCAL YEAR END YEAR SALARY ($) BONUS ($) COMPENSATION ($) (NUMBER)
--------------------------- ---- ---------- --------- ---------------- ------------
<S> <C> <C> <C> <C> <C>
Richard E. Forkey................. 1996 119,600 -0- 23,832(1) -0-
President, Chief Executive Officer 1995 121,413 -0- 18,600(1) -0-
1994 120,726 -0- 13,850(1) -0-
Jack P. Dreimiller................ 1996 109,986 -0- 4,794(2) -0-
Senior Vice President Finance 1995 101,950 1,000 3,384(2) 75,000
and Chief Financial Officer 1994 96,481 -0- -0- -0-
Robert C. Meinhold................ 1996 102,963 -0- 4,493(2) -0-
Vice President 1995 96,087 1,000 3,191(2) 60,000
Sales and Marketing 1994 91,515 -0- -0- -0-
- ---------------
<FN>
(1) Includes $5,145 and $3,971 for Company contribution to Profit Sharing Plan
in 1996 and 1995, respectively, and $10,595, $6,736 and $5,962 for car
expense and $6,688, $6,688 and $6,888 for premiums for a life insurance
policy and a disability insurance policy for 1996, 1995, and 1994,
respectively.
(2) Represents Company contribution to Profit Sharing Plan.
</TABLE>
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION
VALUES
<TABLE>
The following table summarizes for each of the named executive officers the
total number of unexercised options, if any, held at June 30, 1996 and the value
of unexercised in-the-money options, if any, held at June 30, 1996. In-the-money
options are options where the fair market value of the underlying securities
exceeds the exercise or base price of the option. The value of unexercised,
in-the-money options at fiscal year-end is the difference between the exercise
price of the option and the fair market value of the underlying stock on June
30, 1996, which was $1.88 per share. The underlying options have not been
exercised, and actual gains, if any, on exercise will depend on the value of the
Company's Common Stock on the date of exercise. None of the named executive
officers exercised any stock option during the fiscal year ended June 30, 1996.
<CAPTION>
FISCAL-YEAR-END OPTION VALUES
UNEXERCISED OPTIONS VALUE OF UNEXERCISED
AT FISCAL-YEAR END IN-THE-MONEY OPTIONS
------------------------------- AT FISCAL YEAR-END ($)
EXERCISABLE UNEXERCISABLE -------------------------------
NAME (NUMBER) (NUMBER) EXERCISABLE UNEXERCISABLE
---- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
Richard E. Forkey.................... -0- -0- -0- -0-
Jack P. Dreimiller................... 25,000 50,000 12,500 25,000
Robert C. Meinhold................... 24,000 36,000 12,000 18,000
</TABLE>
4
<PAGE> 8
LONG TERM INCENTIVE PLANS--AWARDS IN LAST FISCAL YEAR
The Company has no long term incentive plan.
EMPLOYMENT CONTRACTS AND TERMINATION OF EMPLOYMENT ARRANGEMENTS
The Company has no employment contracts in place with any named executive
officers. The Company also has no compensatory plan or arrangement with respect
to any named executive officer where such plan or arrangement will result from
the resignation, retirement, or any other termination of such executive
officer's employment with the Company and its subsidiaries or from a change in
control of the Company or a change in the named executive officers'
responsibilities following a change-in-control.
DIRECTOR COMPENSATION
The Company pays each director who is not also an employee of the Company
$250.00 per meeting which the director attends and reimburses the director for
travel expenses.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The Company has an arrangement with J.R. Pitlor ("J.R. Pitlor"), a company
wholly owned by Mr. Pitlor, a director of the Company, under which Mr. Pitlor
provides consulting services to the Company for a fee not to exceed $5,000 a
month. Either party may terminate this arrangement at will. The Company paid
J.R. Pitlor for consulting services aggregate fees of approximately $180,000
from July 1, 1993 to June 30, 1996.
The Company leases its facility in Gardner, Massachusetts from Equity
Assets, Inc. ("Equity"), a company wholly owned by Mr. Forkey, the President and
Treasurer and a director of the Company, under a Lease Agreement dated January
2, 1989, at an annual base rent of $108,000. The Company pays Equity in monthly
installments of $9,000. The lease expires December 31, 1999.
The Company has paid legal fees to Ropes & Gray, a law firm of which Mr.
Benjamin, the Clerk and a director of the Company, is a partner, of
approximately $107,570 for fiscal year 1994, $34,478 for fiscal year 1995, and
$29,510 for fiscal year 1996.
5
<PAGE> 9
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT
<TABLE>
The following table sets forth information regarding the Company's Common
Stock owned as of the close of business on September 30, 1996, the record date
for the 1996 Annual Meeting, by the following persons: (i) each person who is
known by the Company to own beneficially more than 5% of the Company's Common
Stock, (ii) each of the Company's directors and nominees for director who
beneficially owns the Company's or its subsidiaries' Common Stock, other than
directors' qualifying shares, (iii) each of the Company's most highly paid
executive officers whose cash compensation exceeds $100,000 who beneficially
owns the Company's or its subsidiaries' Common Stock, and (iv) all executive
officers and directors, as a group, who beneficially own the Company's or its
subsidiaries' Common Stock. The information on beneficial ownership in the table
and footnotes thereto is based upon data furnished to the Company by, or on
behalf of, the person listed in the table.
<CAPTION>
AMOUNT AND
NATURE OF
NAME AND ADDRESS BENEFICIAL
OF BENEFICIAL OWNER OWNERSHIP(1) PERCENT(2)
------------------- ------------ ----------
<S> <C> <C>
FIVE PERCENT HOLDERS
- --------------------
Equity Securities Trading Co., Inc............................... 638,719(3) 10.68%
2820 IDS Center
Minneapolis, Minnesota 55402
DIRECTORS AND OFFICERS
- ----------------------
Edward A. Benjamin*.............................................. 12,500(4) **
c/o Ropes & Gray
One International Place
Boston, MA 02110
Richard E. Forkey*............................................... 1,786,017 29.86%
c/o Precision Optics Corporation, Inc.
22 East Broadway
Gardner, MA 01440
Joel R. Pitlor*.................................................. 100,117(5) 1.65%
c/o J.R. Pitlor
19 Chalk Street
Cambridge, MA 02139
Robert R. Shannon*............................................... 29,000(6) **
7040 E. Taos Place
Tucson, AZ 85715
Jack P. Dreimiller............................................... 25,000(6) **
c/o Precision Optics Corporation, Inc.
22 East Broadway
Gardner, MA 01440
Robert C. Meinhold............................................... 24,000(6) **
c/o Precision Optics Corporation, Inc.
22 East Broadway
Gardner, MA 01440
All officers and directors as a group, including those named
above (6 persons).............................................. 1,976,634(7) 32.19%
</TABLE>
6
<PAGE> 10
- ---------------
* Director
** The percentage of shares beneficially owned by such person does not exceed
one percent of the Company's Common Stock.
(1) Represents shares with respect to which each beneficial owner listed has or
will have, upon acquisition of such shares, sole voting power and investment
power.
(2) Percentages are calculated on the basis of the amount of outstanding Common
Stock plus, for each person or group, any securities that person or group
has the right to acquire within sixty days pursuant to options, warrants,
conversion privileges, or other rights.
(3) Based on the Schedule 13G dated December 31, 1993, wherein Equity Trading
Securities Co., Inc. reported the beneficial ownership of 638,719 shares of
the Company's Common Stock.
(4) Includes 7,500 shares which may be acquired within sixty days upon the
exercise of outstanding stock options.
(5) Includes 75,117 shares which may be acquired within sixty days upon the
exercise of outstanding stock options.
(6) Represents shares which may be acquired within sixty days upon the exercise
of outstanding stock options.
(7) Includes 160,617 shares which may be acquired within sixty days upon the
exercise of outstanding stock options.
INDEPENDENT PUBLIC ACCOUNTANTS
The directors have appointed Arthur Andersen LLP to examine the Company's
financial statements for fiscal year 1997. The Company expects that a
representative of Arthur Andersen LLP will be present at the annual meeting and
available to respond to appropriate questions and will have the opportunity to
make a statement if he or she desires to do so.
SHAREHOLDER PROPOSALS
Shareholders may present proposals for inclusion in the 1997 Proxy
Statement and form of proxy relating to that meeting provided they are received
by the Clerk of the Company no later than June 14, 1997 and are otherwise in
compliance with applicable Securities and Exchange Commission regulations.
7
<PAGE> 11
/X/ Please mark votes
as in this example
<TABLE>
<S> <C> <C> <C> <C> <C> <C>
With-
For hold
PRECISION OPTICS 1) Election of Class III Director. / / / /
CORPORATION, INC. The nominee for the Board of
Directors to serve for a three-
year term as Class III Director is
Robert R. Shannon
Please be sure to sign and date this Proxy. Date
--------------------------- Mark box at right if comments / /
or address change have been
- ------------------------------------- -------------------------------------- noted on the reverse side of
Shareholder sign here Co-owner sign here this card.
</TABLE>
Detach card Detach Card
PRECISION OPTICS CORPORATION, INC.
Dear Shareholder:
Please take note of the important information enclosed with this Proxy
Ballot. The Proposal, which is discussed in detail in the enclosed proxy
materials, requires your immediate attention and approval.
Your vote counts, and you are strongly encouraged to exercise your right to
vote your shares.
Please mark the boxes on the proxy card to indicate how your shares shall
be voted. Then sign and date the card, detach it, and return your proxy
vote in the enclosed postage paid envelope.
Your vote must be received before the Annual Meeting of Shareholders on
November 12, 1996. Thank you in advance for your prompt consideration of
these matters.
Very truly yours,
Precision Optics Corporation, Inc.
<PAGE> 12
PRECISION OPTICS CORPORATION, INC.
Common Stock Proxy
The undersigned, revoking any previous instructions, hereby acknowledges receipt
of the Notice and Proxy Statement dated October 11, 1996. In connection with the
Annual Meeting mentioned below, the undersigned hereby appoint(s) Richard E.
Forkey and Edward A. Benjamin as attorneys of the undersigned, each with power
to act alone and with full power of substitution, to act and to vote all shares
of stock which the undersigned is entitled to vote at the Annual Meeting of
Shareholders of Precision Optics Corporation, Inc. to be held on November 12,
1996, a 10:00 A.M. at the Westminster Village Inn Road, Westminster,
Massachusetts, and at any adjournment or postponement thereof, upon the matters
set forth in the proxy statement for such Annual Meeting. The foregoing
attorneys are authorized to vote, in their discretion, upon such other business
as may properly come before the meeting or any adjournments or postponements
thereof.
THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS. WHEN THIS PROXY IS PROPERLY
EXECUTED, THE SHARES REPRESENTED HEREBY WILL BE VOTED AS SPECIFIED BY THE
SHAREHOLDER(S) ON THE REVERSE SIDE HEREOF OR, WHERE NO DIRECTION IS GIVEN, WILL
BE VOTED FOR THE ELECTION OF THE CLASS III DIRECTOR NOMINEE.
PLEASE VOTE AND SIGN ON OTHER SIDE AND RETURN PROMPTLY IN ENCLOSED ENVELOPE.
Please sign this proxy exactly as your name appears on the books of the Company.
Joint owners should each sign personally. If signing as attorney, executor,
administrator, trustee, guardian, or other fiduciary, please give your full
title as such, and where more than one name appears, a majority must sign. If a
corporation, this signature should be that of an authorized officer who should
state his or her title.
HAS YOUR ADDRESS CHANGED? DO YOU HAVE ANY COMMENTS?
- --------------------------------------- -----------------------------------
- --------------------------------------- -----------------------------------
- --------------------------------------- -----------------------------------
-2-
<PAGE> 13
ATTACHMENT A
Your
Partner
with a
Vision
PRECISION OPTICS CORPORATION
[Graphic of Rectangle]
<PAGE> 14
President's Letter September 30, 1996
Fiscal year 1996 was Precision Optics Corporation's third consecutive year
of record sales, profitable operations, significant new products and important
growth in technology and production capacity. With net income of $406,000 on
sales of $8.1 million, the Company finished the year with a strong balance
sheet, growing acceptance in traditional markets, and major emerging
opportunities in the semiconductor and optical communication markets.
Among the year's accomplishments:
New Products in Current Markets
- In late summer 1996 we completed customer testing of our new
arthroscope, paving the way for production shipments starting this
fall.
- We are close to the release of yet another new generation of
endocouplers designed to build on the very strong market acceptance of
our current product line.
- New endoscopic instruments for a number of current customers in at
least four medical specialties are in development.
- We developed and produced prototype lots of three advanced
night-vision lens systems, including a night vision system that could
go into production for the United States government by fiscal year
1998.
New Technology and Production Capacity
- We brought two advanced optical thin film production systems on line
in early 1996.
- Our new optical shop achieved successful production runs of ultra-high
quality prisms, micro-optics and other specialized optics for a
variety of medical, industrial and other applications.
- By mid-year we were producing endoscope micro-prisms internally,
enabling a major increase in future gross margins on endocscope
products.
- With a new 8,500 square-foot facility up and running in January 1996,
we increased total production area by more than half and peak
production rates by over 30% to 6,000 instruments per month.
New Major Markets
- By April, entry level thin film contracts were received for initial
quality trials in the semiconductor device market.
- We have also nearly completed work under a production contract for
special prisms and thin films used in semiconductor production
equipment.
- Three potential customers are presently testing our new thin films for
optical communication devices.
These highlights suggest the Company's growing internal and aggressive
positioning in current and new markets as of the end of fiscal year 1996. Over
the last three years we have achieved solid incremental growth by pursuing
important niches in our traditional medical and night-
<PAGE> 15
vision markets. At the same time, we have begun to address broader growth
opportunities in prospective high-margin markets that match our capabilities.
Looking forward, we are excited by the potential for sales growth, profitability
and the appreciation of shareholder value, and we are confident in the ability
of our people and technology to carry us to new levels of achievement. As
always, we are grateful for the support of our shareholders, staff, Board of
Directors, customers and associates. With your continued support, we have high
expectations for fiscal years 1997 and beyond.
Richard E. Forkey
President
<PAGE> 16
Front Cover Photo
Precision Optics new world class manufacturing facility in Fitchburg,
Massachusetts
[Graphic of opticians]
Skilled optical technicians assemble state-of-the-art medical products to POC's
own demanding quality specifications.
Precision Optics Corporation is a recognized expert in advanced lens
design, image analysis, optical systems design, structural design and
analysis, prototype production and evaluation, optical testing, and high
volume optical systems manufacture.
Typical production rates are up to several thousand per month. Areas of
special expertise include the production of lens systems and special
optical thin film systems for optical character readers, precision optical
registration devices and laser processing.
Presently, POC is the only qualified American supplier of production lens
systems for advanced generation military night-vision goggles. The
Company's full line of high performance American-made medical instruments
for the OEM market includes rigid endocscopes, endoscopic eyepieces and
endocouplers for flexible endocscopes, various special purpose endocouplers
and beamsplitters, and specialty endoscopes.
New POC optics shop provides security in sourcing unique,
difficult to make optics.
[Graphic of optics shop]
<PAGE> 17
January of 1996 saw many
changes in Precision Optics
Corporation's ability to serve
its customers. POC has
expanded its assembly and
testing capabilities by moving
these departments to a new
8,500 square foot facility.
This has enabled POC to follow
through on plans for in-house
production of unique
components, by establishing
our own state-of-the-art
optics shop. This, combined
with the installation of two
Leybold A-1100 coating
chambers, positions POC for
entry into high growth areas
such as Telecommunications,
Machine Vision and
Semiconductor
Microlithography.
POC has proven leadership and expertise in all phases of optical development and
production. POC produces quality thin films in advanced clean room facilities
for applications ranging from ultraviolet to near infrared in experimental runs
or volume production.
These durable coatings perform to our customers' specifications: low
absorption/high-reflection, partial reflection, anti-reflection, conductive, or
other specialized spectral properties including developmental coatings for a
variety of substrates such as ceramics, metals, glass, plastic, and crystals.
POC manufactures optical thin films with advanced, state-of-the-art
instrumentation (ion sources, sputtering, electron beam deposition systems,
optical monitors and crystal monitors) for precise control and repeatable thin
film processes.
[Graphic of Microprocessors]
Leybold Model A-1100 thin film coating systems with ion sources and Leycom III
Microprocessors provide automatic, repeatable and precise control of thin film
processes.
<PAGE> 18
[Graphic of coating capabilities]
POC's Coating capabilities allow participation in the Optical Telecommunications
Machine Vision, and Semiconductor Microlithography markets.
[Graphic of Arthroscope]
POC-30 4 mm 30[degree] Arthroscope
Precision Optics Arthroscopes have been designed to provide bright high quality
imagery, with an emphasis on very little distortion--almost negligible compared
to all others.
Precision Optics has long been in the business of manufacturing and marketing
optical devices to couple various endoscopes to video and still cameras.
Continuing POC's commitment to providing the medical community with
state-of-the-art instrumentation, these POC Arthroscopes represent a significant
addition to the Company's medical optics product line.
<PAGE> 19
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended June 30, 1996
Commission File Number 001-10647
PRECISION OPTICS CORPORATION, INC.
(Name of small business issuer in its charter)
MASSACHUSETTS 04-279-5294
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
22 EAST BROADWAY
GARDNER, MASSACHUSETTS 01440
(Address of principal executive offices) (Zip Code)
Issuer's telephone number is (508) 630-1800
Securities registered pursuant to Section 12(b) of the Act:
Name of each exchange on
Title of each class which registered
------------------- ----------------
COMMON STOCK, $.01 PAR VALUE BOSTON STOCK EXCHANGE, INC.
Securities registered pursuant to Section 12(g) of the Act: None
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15 of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes X No
--- ---
Check if no disclosure of delinquent filers to Item 405 of Regulation S-B
is contained in this form, and no disclosure will be contained, to the best of
registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB. X
---
The issuer's revenues for its most recent fiscal year were $8,055,271.
The aggregate market value of the voting stock, consisting solely of common
stock, held by non-affiliates of the issuer computed by reference to the closing
price of such stock was $7,808,409 as of June 30, 1996.
The number of shares of outstanding common stock of the issuer as of August
31, 1996 was 5,980,502.
DOCUMENTS INCORPORATED BY REFERENCE
The issuer's Proxy Statement for the 1996 Annual Meeting of Shareholders to
be held on November 12, 1996 is incorporated into Part III of this Form 10-KSB.
Page 1 of 31
<PAGE> 20
PART I
ITEM 1. BUSINESS
--------
Business Development.
- ---------------------
Precision Optics Corporation, Inc. (the "Company") designs, develops,
manufactures, and sells specialized optical systems and components and optical
thin film coatings.
The Company completed a private placement of 1,000,000 shares of Common
Stock in August 1990, an initial public offering of 1,200,000 shares of Common
Stock in November 1990, and a public offering of 1,176,250 shares of Common
Stock in February 1992. In conjunction with these offerings, the Company issued
warrants for a total of 320,000 shares of Common Stock to the selling agent and
underwriters for the offerings. Before these offerings, the Company was
privately held. Precision Optics Corporation, Inc. was incorporated in
Massachusetts in 1982.
In August 1992, the Company established a wholly-owned subsidiary in Hong
Kong to market and sell the Company's products throughout the Pacific Rim
marketplace and to engage in general activities relating to the Company's
business. Also in August 1992, the Company established a wholly-owned
subsidiary, Precise Medical, Inc. ("Precise Medical"), to market and sell
medical video endoscopy systems that incorporated the Company's products
directly to end users (hospitals, physicians, etc.). On July 14, 1993, the
Company closed Precise Medical because of its inability to achieve acceptance in
the medical video systems marketplace.
References to the Company contained herein include its two wholly-owned
subsidiaries except where the context otherwise requires.
Business of Issuer.
- ------------------
The Company designs, develops, manufactures, and sells specialized optical
systems and components and optical thin film coatings. The Company conducts
business in one industry segment only. The Company's products and services fall
into the following areas: medical products for use by hospitals and physicians,
industrial optical products and services and advanced optical system design and
development services and products, primarily under contract either directly or
indirectly with the United States Government ("the Government").
PRINCIPAL PRODUCTS AND SERVICES AND METHODS OF DISTRIBUTION
MEDICAL PRODUCTS. The Company's medical products are endoscopes and image
couplers, beamsplitters, and adapters, which are used as accessories to
endoscopes.
In January 1991, the Company began the design and development of
endoscopes using various optical technologies for use in a variety of minimally
invasive surgical and diagnostic procedures throughout the human body. The
Company's endoscope sales have been primarily to manufacturers of video cameras
and medical products and video endoscopy systems. In addition to its existing
line of endoscopes, the Company is continuing to develop different types of
endoscopes that incorporate varying types of construction and technology for
varying medical specialties and functionality.
-2-
<PAGE> 21
The Company developed and has manufactured and sold since 1985 a
proprietary product line of state-of-the-art instrumentation to couple
endoscopes to video cameras. Included in this product line are image couplers,
which physically connect the endoscope to the video camera system and transmit
the image viewed through the scope to the video camera. Another product -- the
beamsplitter -- performs the same function while preserving for the viewer an
eyeport for direct, simultaneous viewing through the endoscope. The Company has
sold these devices primarily to endoscope and video camera manufacturers and
suppliers for resale under its customers' names.
The Company's image couplers and beamsplitters can withstand
surgery-approved sterilization. The Company also offers autoclavable image
couplers, which are able to withstand sterilization in superheated steam under
pressure. Autoclavability is a preferred method of sterilization because of its
relative speed, safety, and efficiency. The Company believes there is a trend
toward increased sterilization of medical instruments and that it is the only
company in the world that produces autoclavable image couplers. The Company has
investigated the development of an autoclavable beamsplitter. Although
autoclavable endoscopes and video cameras, the necessary components to a fully
autoclavable video-monitored endoscopy, are not yet available, the Company is in
the process of developing an autoclavable endoscope and believes that video
camera manufacturers are attempting to develop autoclavable video cameras.
There can be no assurance as to the general market acceptance of any of the
Company's new products.
Included in the Company's medical products sales are sales of image
couplers and beamsplitters for video-monitored examination of a variety of
industrial cavities and interiors. The Company has developed, and may develop in
the future, specialized borescopes for industrial applications.
ADVANCED OPTICAL DESIGN AND DEVELOPMENT SERVICES. The Company provides on a
contract basis advanced lens design, image analysis, optical system design,
structural design and analysis, prototype production and evaluation, optics
testing, and optical system assembly. Some of the Company's development
contracts have led to optical system production business for the Company, and
the Company believes its prototype development service may lead to new product
production from time to time.
Within the advanced optical design and development area, the Company's
sales recently have been largely of night-vision products and services. The
Company designs, manufactures, and sells night-vision optical systems and
components that permit users to see in extreme low light.
Under contract with a customer that produces and sells aviation
night-vision goggles to the United States Army, the Company has designed and
produced the eyepieces for aviators' night-vision goggles. Under contract with
the same customer, the Company designed and currently produces collimator
assemblies for night-vision goggles used by ground personnel.
Under additional design and development contracts with the same customer,
the Company has designed an objective lens for aviators' night-vision goggles,
designed and built prototypes of an objective lens for ground personnel goggles,
designed and built new lens system prototypes for night driver's viewers and
armament sites, and designed and built a magnifier attachment for ground
-3-
<PAGE> 22
personnel goggles. In addition, the Company has designed and currently produces
a new objective lens and eyepiece for aviators' night-vision goggles.
The Company has in the past and expects in the future to have difficulty
competing for production contracts for night-vision products due to the lower
prices offered by foreign manufacturers. In addition, Government budget
uncertainties and efforts to lower the federal budget deficit and defense
spending may adversely affect the Company. The Company believes, however, that
some of its night-vision products and development work incorporate new
technology which the Government may use to update its existing equipment.
In addition to its night-vision related design and development, the Company
designs, develops, and manufactures thin film coatings and performs thin film
coatings for use on various optical products. Many of the Company's advanced
optical design and development projects and the manufacture of the Company's
medical and night-vision products have been significantly dependent upon the
Company's thin film capabilities. Presently, optical thin film business not
associated with other Company business and products is limited or very
specialized.
The Company has also developed a lens-prism system which it has sold for
industrial use as part of an automated registration system for machines and has
developed and sells a lens system for optical character reading.
COMPETITION AND MARKETS
The areas in which the Company engages are highly competitive and include
both foreign and domestic competitors. Many of the Company's competitors are
larger and have substantially greater resources than the Company. Furthermore,
other domestic or foreign companies, some with greater experience in the optics
industry and greater financial resources than the Company, may seek to produce
products or services that compete with those of the Company. The Company may
establish or use production facilities overseas to produce key components to the
Company's business, such as lenses. The Company believes that the cost savings
from such production may be essential to the Company's ability to compete on a
price basis in the medical and night-vision optics areas and to the Company's
profitability, and that the Company's inability to establish or maintain such
production facilities could materially, adversely affect the Company.
The Company believes that competition for sales of its products and
services, which have been principally sold to OEM customers, is based on
performance and other technical features, as well as other factors, such as
scheduling and reliability, in addition to competitive price.
The Company currently sells its image couplers, beamsplitters, and adapters
to a market that consists of approximately 30 potential OEM customers, 15 of
which are in the United States. These potential customers sell video cameras,
endoscopes, or video-endoscopy systems. The Company has made sales to
approximately 10 of these customers, most of which are camera suppliers and all
of which are United States companies. The Company estimates that it has
approximately 20% of the market share in these products and anticipates growth
in this area. The Company's primary competition in this area is the customers'
own in-house capabilities to manufacture such products. The Company believes
that these customers typically purchase products from the Company, despite their
in-house capabilities, because they choose to devote their own technical
resources to their primary
-4-
<PAGE> 23
products, such as cameras or endoscopes. The Company estimates that
approximately 50% of the market demand for image couplers, beamsplitters, and
adapters is met by "captive" or in-house capabilities. The Company anticipates
increased demand for its autoclavable products because it believes there is a
trend towards more stringent sterilization of medical instruments.
The Company has marketed and sold its endoscopes to OEM video camera and
video endoscopy suppliers for resale under the purchaser's name. A number of
domestic and foreign competitors also sell endoscopes to such OEM suppliers, and
the Company's share of the endoscope market is nominal. The Company believes
that, while its resources are substantially more limited than these competitors,
the Company may be able to be more responsive to the needs of endoscope users.
With respect to the Company's advanced optical design and development
services not related to night-vision or thin film coatings, the Company has
numerous customers and competitors. The ability to supply design and development
services to such customers is highly dependent upon a company's and its
employees' reputations and prior experience.
With respect to night-vision optics, the Company's sales of its products
and services have been almost exclusively to one customer, which sells
night-vision equipment to the United States Army. The Company faces intense
competition for production of night-vision products from foreign manufacturers.
In the night-vision optical design area, the Company has numerous competitors.
The Company's business in the night-vision optics area is highly dependent upon
the Company's reputation and performance, as well as upon Government contracts
and policy. The Company believes the demand for night-vision optics generally,
which are used extensively in drug and law enforcement and surveillance as well
as search and rescue missions and military applications, will lessen. Recent
experience with lens sales for new consumer night vision products also suggests
that market growth in this area is severely limited.
The Company's thin film coatings competitors are numerous and have deep and
broad capabilities.
The Company has had negligible direct export sales to date.
RESEARCH AND DEVELOPMENT
The Company believes that its future success depends to a large degree on
its ability to continue to conceive and to develop new optical products and
services and to enhance the performance characteristics and methods of
manufacture of existing products. Accordingly, it expects to continue to seek to
obtain product-related design and development contracts with customers and to
invest its own funds on its research and development.
The Company received approximately $1,060,000 and $752,000 for the fiscal
years ended June 30, 1996 and 1995, respectively, from customers for
customer-sponsored design and development projects. Levels of customer contract
funded research and development can fluctuate greatly in any given period
depending upon the mix between design efforts and hardware development, which is
generally more expensive and time consuming than the design phases. In addition
to customer-sponsored research and development, the Company spent approximately
$433,000 and $363,000 of its own funds during fiscal years 1996 and 1995,
respectively, on the Company's own research and
-5-
<PAGE> 24
development. The Company expects to continue making significant Company-funded
expenditures for research and development.
RAW MATERIALS AND PRINCIPAL SUPPLIERS
For all of the Company's products, except for thin film coatings, the basic
raw material is precision grade optical glass, which the Company obtains from
several major suppliers. Outside vendors grind and polish all of the Company's
lenses and prisms. For optical thin film coatings, the basic raw materials are
metals and dielectric compounds, which the Company obtains from a variety of
chemical suppliers. The Company believes that its demand for these raw materials
and services is small relative to the total supply and that materials and
services required for the production of its products are currently available in
sufficient production quantities and will be available for fiscal year 1997. The
Company believes, however, that there are relatively few suppliers of the high
quality lenses and prisms which its endoscopes may require. Depending upon the
market acceptance of the Company's endoscopes, the Company may seek to assure
itself of a timely supply of lenses, prisms, or other key materials or
components through the acquisition of a supplier or expanded manufacturing
facilities of its own.
PATENTS AND TRADEMARKS
The Company relies, in part, upon patents, trade secrets, and proprietary
knowledge as well as personnel policies and employee confidentiality agreements
concerning inventions and other creative efforts to develop and to maintain its
competitive position. The Company does not believe that its business is
dependent upon any patent, patent pending, or license, although it believes that
trade secrets and confidential know-how may be important to the Company's
scientific and commercial success.
The Company plans to file for patents, copyrights, and trademarks in the
United States and in appropriate countries to protect its intellectual property
rights whenever possible. The Company holds the rights to two United States
patents and has Japanese and German patent applications pending relating to one
of its image couplers and holds the rights to a United States patent to one of
its endoscopes. The Company has received jointly with a customer a patent
relating to one of its night-vision designs. The Company will assign its rights
under this night-vision patent to such customer for night-vision applications.
The Company knows of no infringements of its patents. Although the Company plans
to protect any patents it has from infringement, it may not be able to pursue
such protection for economic reasons. While the Company believes that its
pending applications relate to patentable devices or concepts, there can be no
assurance that patents will be issued or that any patents issued can be
successfully defended or will effectively limit the development of competitive
products and services.
Although the Company seeks to protect its proprietary information, there
can be no assurance that others will not either develop independently the same
or similar information or gain access to the Company's proprietary information
or that disputes will not arise as to proprietary rights to such information.
The Company's products may now or in the future infringe upon others'
patents or proprietary technology. The Company's defense of any such claims
could have a material, adverse effect on the Company.
-6-
<PAGE> 25
EMPLOYEES
As of June 30, 1996, the Company had fifty-five full-time employees and one
part-time employee.
CUSTOMERS
Sales to the Company's three largest customers, in terms of total sales,
during fiscal year 1996 were approximately 42%, 14% and 12%. Sales to the
Company's two largest customers, in terms of total sales during fiscal year 1995
were approximately 43% and 18%.
ENVIRONMENTAL PROTECTION AND THE EFFECT OF EXISTING OR PROBABLE GOVERNMENT
REGULATIONS ON THE BUSINESS
The Company's operations are subject to a variety of federal, state, and
local laws and regulations relating to the discharge of materials into the
environment or otherwise relative to the protection of the environment. From
time to time the Company uses a small amount of hazardous materials in its
operations. Although the Company believes that it complies with all applicable
environmental laws and regulations, any failure to comply with such laws and
regulations could have a material, adverse effect on its capital expenditures,
earnings, and competitive position.
NEED FOR GOVERNMENT APPROVAL OF PRINCIPAL PRODUCTS OR SERVICES AND EFFECT
OF EXISTING OR PROBABLE GOVERNMENT REGULATIONS ON THE BUSINESS
The Company currently sells and markets four medical products, the
marketing of which may require the permission of the United States Food and Drug
Administration ("FDA"). Pursuant to the Company's notification to the FDA of its
intent to market its laparoscope, additional types of endoscopes which it has
developed and is developing, image coupler, beamsplitter, and adapters, the FDA
has determined that each such device is substantially equivalent to a device
marketed in interstate commerce and that the Company may market such devices,
subject to the general controls provisions of the Food, Drug and Cosmetic Act.
Furthermore, the Company plans to market additional endoscopes and related
medical products that may require the FDA's permission to market such products.
The Company may also develop additional products or seek to sell some of its
current or future medical products in a manner that requires the Company to
obtain the permission of the FDA to market such products, as well as the
regulatory approval or license of other federal, state, and local agencies or
similar agencies in other countries. There can be no assurance that the Company
will be able to maintain the FDA's permission to market its current products or
to obtain such regulatory permission, approvals, or licenses for any of its
other products. Furthermore, potential adverse FDA regulation affecting the
Company which might arise from future legislation or administrative action
cannot be predicted. In addition, FDA regulations may be established that could
prevent or delay regulatory clearances or approval of the Company's products.
The inability of the Company to secure any necessary licenses or regulatory
approvals or permission from the FDA could have a material adverse effect on its
business. The FDA has authority to conduct detailed inspections of manufacturing
plants in order to assure that "good manufacturing practices" are being followed
in the manufacture of medical devices, to require periodic reporting of product
defects to the FDA, and to prohibit the exploitation of devices which do not
comply with law. Failure to comply with applicable regulatory
-7-
<PAGE> 26
requirements can, among other things, result in fines, suspensions of regulatory
clearances or approvals, product recalls, operating restrictions, and criminal
prosecution.
ITEM 2. DESCRIPTION OF PROPERTY
-----------------------
The Company conducts its domestic operations at two facilities in Gardner
and Fitchburg, Massachusetts. The Gardner facility is leased from a corporation
owned by an officer-shareholder-director of the Company, and the Company's
lease expires in December 1999. The Fitchburg facility is under a three year
lease which commenced on November 1, 1995. The Company rents office space in
Hong Kong for sales, marketing, and supplier liaison activities of its Hong Kong
subsidiary.
The Company believes these facilities are adequate for its current
operations; significant increases in production or the addition of significant
equipment additions or manufacturing capabilities in connection with the
production of the Company's line of endoscopes and other products may, however,
require the acquisition or lease of additional facilities. The Company may
establish production facilities domestically or overseas to produce key
assemblies or components, such as lenses, for the Company's products. Overseas
facilities may subject the Company to the political and economic risks
associated with overseas operations. The loss of or inability to establish or
maintain such additional domestic or overseas facilities could materially,
adversely affect the Company's competitive position and profitability.
ITEM 3. LEGAL PROCEEDINGS
-----------------
The Company and its subsidiaries and their property are not party or
subject to any material pending legal proceedings.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
---------------------------------------------------
No matters were submitted to a vote of the Company's security holders
during the fourth quarter of fiscal year 1996.
DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY
The Company's executive officers and directors are as follows:
Position with the Company
Name or Principal Occupation
- ---- -----------------------
Richard E. Forkey President, Treasurer, and Director
Jack P. Dreimiller Senior Vice President, Finance and Chief
Financial Officer
Robert C. Meinhold Vice President, Sales and Marketing
-8-
<PAGE> 27
Edward A. Benjamin Director and Clerk. Mr. Benjamin is a
partner in the law firm of Ropes & Gray,
Boston, Massachusetts
Joel R. Pitlor Director. Mr. Pitlor is president of J.R.
Pitlor, a management consulting firm based
in Cambridge, Massachusetts.
Robert R. Shannon Director. Mr. Shannon is a professor at the
Optical Sciences Center of the University
of Arizona in Tuscon, Arizona.
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
--------------------------------------------------------
The Company's common stock currently trades on the Boston Stock Exchange
under the symbol "POC" and is listed on the National Association of Securities
Dealers Automated Quotation (NASDAQ) System under the symbol "POCI." From
January 1991 to December 1991, the Boston Stock Exchange was the principal
market in which the Company's stock was publicly traded. Since January 1992,
NASDAQ has been the principal market in which the Company's stock is publicly
traded. The high and low sales prices for the Company's stock for each full
quarterly period within the two most recent fiscal years were as follows:
1995 1996
---- ----
Quarter High Low High Low
-----------------------------------------------
First $1 7/8 $1 1/4 $1 7/8 $1 1/8
Second $1 5/8 $1 1/4 $1 7/8 $1 1/4
Third $1 7/16 $1 1/8 $2 $1 1/4
Fourth $1 9/16 $1 $2 $1 1/8
As of August 31, 1996 there were approximately 110 holders of record of the
Company's common stock. The Company has never paid a dividend on its common
stock and does not intend to pay a dividend in the foreseeable future.
-9-
<PAGE> 28
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
-----------------------------------------------------------
AND RESULTS OF OPERATIONS
-------------------------
IMPORTANT FACTORS REGARDING FORWARD-LOOKING STATEMENTS
When used in this discussion, the words "believes", "anticipates", "intends
to", and similar expressions are intended to identify forward-looking
statements. Such statements are subject to certain risks and uncertainties which
could cause actual results to differ materially from those projected. See
"Important Factors Regarding Forward-Looking Statements" filed with the
Company's Quarterly Report on Form 10-QSB for the period ending March 31, 1996
as Exhibit 99 and incorporated herein by reference. Readers are cautioned not to
place undue reliance on these forward-looking statements which speak only as of
the date hereof. The Company undertakes no obligation to release publicly the
result of any revisions to these forward-looking statements which may be made to
reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
LIQUIDITY AND CAPITAL RESOURCES
For the year ended June 30, 1996, the Company's cash and cash equivalents
increased by approximately $90,000 to $2,618,000. The increase in cash and cash
equivalents was due to cash generated by operating activities of approximately
$817,000, less capital expenditures of approximately $616,000, increases in
other assets, primarily patents, of approximately $60,000 and repayment of a
capital lease obligation of approximately $51,000.
During the quarter ending March 31, 1996, the Company entered into a
five-year capital lease obligation for the acquisition of optical thin film
coating equipment totaling approximately $299,000.
The Company intends to continue devoting significant resources to
internally-funded research and development spending on both new products and the
improvement of existing products. The Company also intends to devote resources
to the marketing and product support of its endoscope product line, and the
development of new methods of distribution. These investments may temporarily
result in negative cash flow, but the Company anticipates that the results of
these efforts will translate into increased revenues and profits.
Furthermore, depending upon the market acceptance of the Company's
products, the Company believes that it may be obligated to acquire new
facilities, add additional manufacturing or research and development equipment,
or acquire a business that manufactures or sells to the Company components,
materials, supplies, or services used in the manufacture, marketing,
distribution, or servicing of the Company's new products, as well as the
Company's existing products.
The Company continues to maintain a secured line of credit of $500,000
available with a bank at 1/4% over the prime rate.
The Company's cash and cash equivalents and available lines of credit are
considered sufficient to support working capital and investment needs for the
foreseeable future.
-10-
<PAGE> 29
FISCAL YEAR 1996 RESULTS OF OPERATIONS
Total revenues for the fiscal year 1996 were approximately $8,055,000, an
increase of approximately $477,000 or 6.3%, over fiscal year 1995.
The revenue increase over the prior year was due to higher sales of medical
products (up 30.3%) and higher sales of night vision products (up 1.8%),
partially offset by lower sales of industrial products (down 23.2%). The
increase in sales of medical products was primarily attributable to higher sales
of endocouplers, which increased by 89% for the year to record levels. The
reduction in industrial sales was due primarily to lower sales of industrial
lenses to a significant customer. This customer accounted for 12%, 18%, and 7%
of the Company's total revenues for fiscal years 1996, 1995 and 1994,
respectively. Future sales to this customer, if any, are uncertain at this time.
Gross profits decreased by approximately $123,000 in fiscal year 1996, and
as a percentage of revenues, decreased from 34.1% to 30.6% compared to the
previous year. The decrease in gross profit was due primarily to an unfavorable
shift in sales mix away from industrial products, which have relatively higher
gross margins than other product lines, and higher occupancy and depreciation
expenses related to equipment and manufacturing facilities additions.
For the fiscal years ended June 30, 1996, 1995 and 1994, approximately 45%,
45% and 43% of the Company's total revenues, respectively, were derived from
production and development contracts and subcontracts involving the Government
and its agencies. The Company's current Government business is substantially
comprised of subcontracts with one customer consisting of night- vision advanced
development programs on a cost-plus-fixed-fee basis extending approximately
through September 1996, and two fixed-price production subcontracts for
night-vision lens systems with deliveries scheduled approximately through
September, 1997. The Government may terminate a government contract at any time,
with or without cause. After expiration of the current subcontracts, there can
be no assurance that the Government will award future contracts or subcontracts
or the customers to which it sells.
Selling, general and administrative expenses increased by approximately
$191,000 or 10% in fiscal year 1996 compared to fiscal year 1995. The increase
was due primarily to higher spending on new product research and development,
principally related to medical products, which increased by 19% to approximately
$433,000 in fiscal year 1996, higher advertising expenditures targeted at the
industrial marketplace, and higher depreciation and amortization expenses.
Interest expense relates primarily to capital lease obligations incurred in
the third quarter of fiscal years 1994 and 1996.
Interest income increased by approximately $32,000 in fiscal year 1996 due
to the higher investment base of cash equivalents and higher interest rates.
The provision for income taxes as a percentage of pretax income is lower
than the federal statutory income tax rate primarily due to recognition of
available tax credits and future tax deductions not previously benefited.
-11-
<PAGE> 30
FISCAL YEAR 1995 RESULTS OF OPERATIONS
Total revenues for fiscal year 1995 were approximately $7,578,000, an
increase of approximately $446,000 or 6.3%, over fiscal year 1994.
The revenue increase over the prior year was due primarily to higher sales
of industrial products. Sales of OEM medical and night-vision products were
approximately equivalent to the prior year. Within the OEM medical product line,
sales of endoscopes, while still relatively small, increased by approximately
70% over the prior year.
Gross profit increased by approximately $665,000 in fiscal year 1995, and
as a percentage of revenues, increased from 26.9% to 34.1% compared to fiscal
year 1994. The higher gross profit percentage in fiscal year 1995 was due
primarily to a favorable shift in sales mix to industrial products which have
relatively higher gross margins, and to the recording in fiscal year 1994 of
certain one-time start-up costs related to a night-vision production
subcontract.
Selling, general and administrative expenses increased by approximately
$176,000 or 10% in fiscal year 1995 compared to fiscal year 1994. The increase
was due primarily to higher spending on new product research and development,
principally related to medical products, which increased by 88% to approximately
$363,000 in fiscal year 1995.
Interest expense in fiscal year 1995 and 1994 related primarily to a
capital lease obligation incurred in the third quarter of fiscal year 1995, and
was higher due to a full year of expense in 1995 versus three months in 1994.
Interest income increased by approximately $48,000 in fiscal year 1995 due
to the higher investment base of cash equivalents and higher interest rates.
The provision for income taxes in fiscal year 1995 differed from the amount
computed when applying the United States federal income tax rate to income
before taxes, due primarily to the utilization in fiscal 19995 of net operating
loss and tax credit carryforwards.
ITEM 7. CONSOLIDATED FINANCIAL STATEMENTS
---------------------------------
The Consolidated Financial Statements are filed on pages 13 to 26 of this
Form 10-KSB.
-12-
<PAGE> 31
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
AS OF JUNE 30, 1996 AND 1995
TOGETHER WITH AUDITORS' REPORT
-13-
<PAGE> 32
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To Precision Optics Corporation, Inc.:
We have audited the accompanying consolidated balance sheets of Precision Optics
Corporation, Inc. (a Massachusetts corporation) and subsidiaries as of June 30,
1996 and 1995, and the related consolidated statements of operations,
stockholders' equity and cash flows for each of the three years in the period
ended June 30, 1996. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Precision Optics Corporation,
Inc. and subsidiaries as of June 30, 1996 and 1995, and the results of their
operations and their cash flows for each of the three years in the period ended
June 30, 1996, in conformity with generally accepted accounting principles.
/s/ Arthur Andersen
Boston, Massachusetts
July 24, 1996
-14-
<PAGE> 33
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
<TABLE>
CONSOLIDATED BALANCE SHEETS--JUNE 30, 1996 AND 1995
<CAPTION>
ASSETS 1996 1995
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $2,617,813 $2,527,846
Accounts receivable (net of allowance for doubtful
accounts of approximately $82,000 and $86,000 in
1996 and 1995, respectively) 1,139,804 1,416,371
Inventories 1,863,694 1,468,479
Deferred tax asset 119,000 52,000
Prepaid expenses 44,684 22,874
Refundable income taxes 30,276 --
---------- ----------
Total current assets 5,815,271 5,487,570
---------- ----------
PROPERTY AND EQUIPMENT, AT COST:
Machinery and equipment 2,049,758 1,244,304
Leasehold improvements 420,230 344,718
Vehicles 44,742 33,654
Furniture and fixtures 102,976 88,003
---------- ----------
2,617,706 1,710,679
Less--Accumulated depreciation and amortization 1,531,228 1,246,843
---------- ----------
1,086,478 463,836
---------- ----------
OTHER ASSETS:
Cash surrender value of life insurance policies 52,851 49,057
Patents 125,995 84,000
Deferred costs, net 2,025 3,909
---------- ----------
Total other assets 180,871 136,966
---------- ----------
$7,082,620 $6,088,372
========== ==========
<CAPTION>
LIABILITIES AND STOCKHOLDERS' EQUITY 1996 1995
<S> <C> <C>
CURRENT LIABILITIES:
Accounts payable $ 829,428 $ 467,961
Accrued payroll 81,990 65,006
Accrued profit sharing and bonuses 93,938 140,000
Accrued professional services 49,360 48,855
Accrued vacation 51,881 44,932
Accrued warranty expense 50,000 45,000
Accrued income taxes 35,383 50,784
Other accrued liabilities 51,638 40,654
Current portion of capital lease obligation 82,678 28,686
---------- ----------
Total current liabilities 1,326,296 931,878
---------- ----------
CAPITAL LEASE OBLIGATION, NET OF CURRENT PORTION 278,949 84,829
---------- ----------
COMMITMENTS (Notes 3 and 4)
STOCKHOLDERS' EQUITY:
Common stock, $.01 par value-
Authorized--10,000,000 shares
Issued and outstanding--5,980,502 shares 59,805 59,805
Additional paid-in capital 5,145,655 5,145,655
Retained earnings (deficit) 271,915 (133,795)
---------- ----------
Total stockholders' equity 5,477,375 5,071,665
---------- ----------
$7,082,620 $6,088,372
========== ==========
</TABLE>
The accompanying notes are an integral part of these consolidated
financial statements.
15
<PAGE> 34
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
<TABLE>
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED JUNE 30, 1996, 1995 AND 1994
<CAPTION>
1996 1995 1994
<S> <C> <C> <C>
REVENUES $8,055,271 $7,578,097 $7,131,888
COST OF GOODS SOLD 5,592,871 4,992,785 5,211,575
---------- ---------- ----------
Gross profit 2,462,400 2,585,312 1,920,313
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 2,128,155 1,937,497 1,761,103
---------- ---------- ----------
Operating income 334,245 647,815 159,210
INTEREST EXPENSE (16,639) (9,598) (4,356)
INTEREST INCOME 124,104 92,499 44,203
---------- ---------- ----------
Income before provision for income taxes 441,710 730,716 199,057
PROVISION FOR INCOME TAXES 36,000 150,000 --
---------- ---------- ----------
Net income $ 405,710 $ 580,716 $ 199,057
========== ========== ==========
INCOME PER COMMON AND COMMON EQUIVALENT SHARE $ .07 $ .10 $ .03
========== ========== ==========
WEIGHTED AVERAGE COMMON AND COMMON EQUIVALENT
SHARES OUTSTANDING 6,116,569 6,066,366 6,085,275
========== ========== ==========
</TABLE>
The accompanying notes are an integral part of these consolidated
financial statements.
16
<PAGE> 35
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
<TABLE>
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED JUNE 30, 1996, 1995 AND 1994
<CAPTION>
RETAINED
ADDITIONAL EARNINGS TOTAL
NUMBER OF COMMON PAID-IN (ACCUMULATED STOCKHOLDERS'
SHARES STOCK CAPITAL DEFICIT) EQUITY
<S> <C> <C> <C> <C> <C>
BALANCE, JUNE 30, 1993 5,707,626 $57,076 $4,974,289 $(913,568) $4,117,797
Proceeds from exercise of
options to purchase common
stock 272,876 2,729 23,366 -- 26,095
Net income -- -- -- 199,057 199,057
--------- ------- ---------- --------- ----------
BALANCE, JUNE 30, 1994 5,980,502 59,805 4,997,655 (714,511) 4,342,949
Tax benefit from exercise of
options to purchase common
stock -- -- 148,000 -- 148,000
Net income -- -- -- 580,716 580,716
--------- ------- ---------- --------- ----------
BALANCE, JUNE 30, 1995 5,980,502 59,805 5,145,655 (133,795) 5,071,665
Net income -- -- -- 405,710 405,710
--------- ------- ---------- --------- ----------
BALANCE, JUNE 30, 1996 5,980,502 $59,805 $5,145,655 $ 271,915 $5,477,375
========= ======= ========== ========= ==========
</TABLE>
The accompanying notes are an integral part of these consolidated
financial statements.
17
<PAGE> 36
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
<TABLE>
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 1996, 1995 AND 1994
<CAPTION>
1996 1995 1994
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 405,710 $ 580,716 $ 199,057
Adjustments to reconcile net income to net cash provided
by (used in) operating activities-
Depreciation and amortization 308,275 184,849 121,212
Deferred income taxes (67,000) (52,000) --
Changes in assets and liabilities-
Accounts receivable 276,567 (123,485) (467,119)
Inventories (395,215) 86,378 (187,446)
Prepaid expenses (21,810) (4,091) 8,499
Refundable income taxes (30,276) -- 31,069
Accounts payable 361,467 16,732 (94,173)
Accrued payroll 16,984 (5,527) (2,246)
Accrued profit-sharing and bonuses (46,062) 140,000 --
Accrued professional services 505 (3,238) (23,523)
Accrued income taxes (15,401) 47,722 --
Accrued restructuring -- (4,695) (133,466)
Other accrued liabilities 22,933 (17,413) 11,158
---------- ---------- ----------
Net cash provided by (used in) operating activities 816,677 845,948 (536,978)
---------- ----------- ----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (615,798) (115,602) (171,206)
(Increase) decrease in other assets (59,844) (47,717) 1,718
---------- ----------- ----------
Net cash used in investing activities (675,642) (163,319) (169,488)
---------- ----------- ----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of capital lease obligation (51,068) (26,603) (11,461)
Tax benefit from stock options exercised -- 148,000 --
Proceeds from issuance of common stock -- -- 26,095
---------- ----------- ----------
Net cash provided by (used in) financing activities (51,068) 121,397 14,634
---------- ----------- ----------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 89,967 804,026 (691,832)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 2,527,846 1,723,820 2,415,652
---------- ---------- ----------
CASH AND CASH EQUIVALENTS, END OF YEAR $2,617,813 $2,527,846 $1,723,820
========== ========== ==========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid (received) during the year for-
Interest $ 16,639 $ 9,598 $ 4,356
========== ========== ==========
Income taxes $ 151,325 $ 6,278 $ (29,613)
========== ========== ==========
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTMENT ACTIVITIES:
Capital lease obligation $ 299,180 $ -- $ 151,579
========== ========== ==========
</TABLE>
The accompanying notes are an integral part of these consolidated
financial statements.
18
<PAGE> 37
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Business
Precision Optics Corporation, Inc. (the Company) designs, manufactures and
sells optical systems, components and thin-film coatings. The Company
conducts business in one industry segment only and its customers are
primarily domestic. The Company's products and services fall into two
principal areas: medical products for use by hospitals and physicians and
advanced optical system design and development services and products,
primarily under contract either directly or indirectly with the United
States Government.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of
the Company and its two wholly owned subsidiaries, Precise Medical,
Incorporated, which was inactivated during fiscal 1994, and Wood's
Precision Optics Corporation, Ltd. All significant intercompany accounts
and transactions have been eliminated in consolidation.
Revenues
Revenues for industrial and medical products sold in the normal course of
business are recognized upon shipment. Contract revenues are recognized
under the percentage-of-completion method. The percentage of completion is
determined by computing the percentage of the actual cost of work performed
to the anticipated total contract costs, or on the basis of units shipped.
When the estimate on a contract indicates a loss, the Company's policy is
to record the entire loss in the current period.
Cash and Cash Equivalents
The Company includes in cash equivalents all highly liquid investments with
original maturities of three months or less at the time of acquisition.
Cash equivalents at June 30, 1996 and 1995 include approximately $1,455,000
and $1,880,000, respectively, of United States Treasury bills.
19
<PAGE> 38
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996
(Continued)
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Inventories
<TABLE>
Inventories are stated at the lower of cost (first-in, first-out) or market
and include material, labor and manufacturing overhead. The components of
inventories are as follows at June 30, 1996 and 1995:
<CAPTION>
1996 1995
<S> <C> <C>
Raw material $1,282,924 $ 915,932
Work-in-progress 502,658 391,318
Finished goods 78,112 161,229
---------- ----------
$1,863,694 $1,468,479
========== ==========
</TABLE>
Depreciation and Amortization
<TABLE>
The Company provides for depreciation and amortization by charges to
operations, using the straight-line and declining-balance methods, which
allocate the cost of property and equipment over the following estimated
useful lives:
<CAPTION>
ESTIMATED
ASSET CLASSIFICATION USEFUL LIFE
<S> <C>
Machinery and equipment 5-7 Years
Leasehold improvements Life of lease
Vehicles 3 Years
Furniture and fixtures 5 Years
</TABLE>
Significant Customers and Concentration of Credit Risk
Revenues from the Company's three largest customers were approximately 42%,
14% and 12%, respectively, of total revenues for the year ended June 30,
1996. Revenues from the Company's two largest customers were approximately
43% and 18%, respectively, of total revenues for the year ended June 30,
1995. Revenues from the Company's largest customer were approximately 51%
of total revenues for the year ended June 30, 1994. No other customers
accounted for more than 10% of the Company's revenues in each of the three
years ended June 30, 1996. At June 30, 1996 and 1995, receivables from the
Company's largest customer were approximately 58% and 44% of total accounts
receivable, respectively.
20
<PAGE> 39
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996
(Continued)
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Significant Customers and Concentration of Credit Risk (Continued)
Approximately 44%, 45% and 43% of the Company's revenues for the years
ended June 30, 1996, 1995 and 1994, respectively, were derived from sales
to agencies of the government or customers that supply agencies of the
government.
Research and Development
Research and development costs, which are expensed as incurred, are
included in selling, general and administrative expenses and include direct
costs plus overhead. Such costs totaled approximately $433,000, $363,000
and $193,000 for the years ended June 30, 1996, 1995 and 1994,
respectively.
Income per Common and Common Equivalent Share
Income per common and common equivalent share is computed based on the
weighted average number of common and common equivalent shares (if
dilutive) outstanding during each year. The difference between the weighted
average shares outstanding under the primary and fully diluted methods is
not significant.
Foreign Currency Translation
The Company translates certain accounts and financial statements of its
foreign subsidiary in accordance with SFAS No. 52, Foreign Currency
Translation. The functional currency of the Company's foreign subsidiary is
the United States dollar. Accordingly, translation gains or losses are
reflected in the accompanying consolidated statements of operations and
have not been significant.
Other Assets
Patents and deferred costs are carried at cost, less accumulated
amortization of approximately $60,000 and $44,000 at June 30, 1996 and
1995, respectively. Such costs are amortized using the straight-line method
over their legal or estimated useful lives, generally five to seventeen
years.
21
<PAGE> 40
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996
(Continued)
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.
Reclassifications
Certain reclassifications have been made to the prior years' balances to
conform with the current year's presentation.
(2) LINE OF CREDIT
At June 30, 1996, the Company had available a demand line of credit of
$500,000 at an interest rate equal to the bank's prime rate (8.25% at June
30, 1996) plus 0.25%. At June 30, 1996, there were no borrowings
outstanding under this line of credit. Borrowings under this line of credit
are secured by all assets of the Company. The line of credit expires on
November 30, 1996; however, the Company anticipates renewal.
(3) CAPITAL LEASE OBLIGATION
<TABLE>
At June 30, 1996, future minimum lease payments under capital lease
obligations are as follows:
<CAPTION>
FISCAL YEAR AMOUNT
<S> <C>
1997 $109,000
1998 109,000
1999 93,920
2000 72,808
2001 42,474
--------
Total minimum lease payments 427,202
Amount representing interest (65,575)
--------
Present value of minimum lease payments 361,627
Less--Current portion 82,678
--------
$278,949
========
</TABLE>
22
<PAGE> 41
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996
(Continued)
(3) CAPITAL LEASE OBLIGATION (Continued)
Capital leases are secured by all assets of the Company under a security
agreement subordinate to the Company's demand line of credit.
(4) RELATED PARTY TRANSACTIONS AND COMMITMENTS
The Company leases one of its facilities from a corporation owned by an
officer of the Company. The lease, which was renewed during fiscal 1995,
terminates in December 1999 and requires lease payments of $9,000 per
month. The Company may terminate the lease as of the end of any calendar
year during the term by providing written notice to the lessor by June 30
of such year.
Total future minimum rental payments under all operating leases for fiscal
1997 are $208,000.
Rent expense on operating leases was approximately $187,000, $144,000 and
$133,000 for the years ended June 30, 1996, 1995 and 1994, respectively.
The Company paid fees to a director of approximately $60,000 during each of
fiscal 1996, 1995 and 1994 for consulting services. Another director is a
partner in a law firm that has performed legal services for the Company
during fiscal 1996, 1995 and 1994.
(5) STOCKHOLDERS' EQUITY
In conjunction with previous equity offerings, the Company issued warrants
to acquire a total of 320,000 shares of common stock, of which warrants for
23,500 shares expired during fiscal 1996. Warrants for 76,500 shares have
an exercise price of $4.50 per share and expire on January 15, 1997.
Warrants for 220,000 shares expire on October 23, 1998 and have an exercise
price of $1.375 per share. As of June 30, 1996, all of these warrants were
exercisable.
During 1989, the stockholders approved a stock option plan (the Plan) for
key employees. The Plan, as amended, authorizes the grant of options to
purchase up to 1,110,000 shares of the Company's common stock at an
exercise price not less than 100% of the fair market value per share at the
date of grant. Options granted are exercisable for a period determined by
the Board of Directors, not to exceed 10 years from the date of grant. At
June 30, 1996, 200,748 shares of common stock were available for future
grants under the Plan.
23
<PAGE> 42
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996
(Continued)
(5) STOCKHOLDERS' EQUITY (Continued)
<TABLE>
The following is a summary of transactions in the Plan for the three years
ended June 30, 1996:
<CAPTION>
NUMBER OPTION PRICE
OF SHARES PER SHARE
<S> <C> <C>
Options outstanding, June 30, 1993 582,876 $.067-$5.6875
Exercised (272,876) .067-.50
Canceled (15,000) 4.4375
--------- -------------
Options outstanding, June 30, 1994 295,000 3.500-5.6875
Granted 395,000 1.3750
Canceled (295,000) 3.500-5.6875
--------- -------------
Options outstanding, June 30, 1995 395,000 1.375
Granted 60,000 1.375-1.50
--------- -------------
Options outstanding, June 30, 1996 455,000 $ 1.375-$1.50
========= =============
Options exercisable, June 30, 1996 164,834 $ 1.375-$1.50
========= =============
</TABLE>
In addition, the Company has granted options outside the Plan, primarily to
directors and consultants at 100% of the fair market value per share at the
date of grant. During fiscal 1995, options for 30,000 shares at $1.375 per
share, including options for 15,000 shares issued to replace existing
options, were granted to two directors of the Company, which became
exercisable in four equal annual installments beginning on December 15,
1994. Also during fiscal 1995, options for 35,000 shares at $1.375 per
share, including options for 15,000 shares issued to replace existing
options, were granted to two consultants and one former employee of the
Company; 15,000 such shares were exercisable at December 15, 1994, and
20,000 shares became exercisable in four equal annual installments
beginning on December 15, 1994. During fiscal 1996, options for 60,000
shares at $1.30 per share were granted to a consultant to the Company,
which became exercisable in five equal annual installments beginning on
July 31, 1995. As of June 30, 1996, options for 221,617 shares were
outstanding at exercise prices ranging from $.067 to $5.6875 per share, of
which 148,617 were exercisable within the same exercise price range.
24
<PAGE> 43
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996
(Continued)
(6) INCOME TAXES
The Company accounts for income taxes in accordance with SFAS No. 109,
Accounting for Income Taxes, whereby a deferred tax asset or liability is
measured by the enacted tax rates that would be in effect when any
differences between the financial statement and tax bases of assets and
liabilities reverse.
<TABLE>
The provision for income taxes in the accompanying consolidated statements
of operations consists of the following for the three years ended June 30,
1996:
<CAPTION>
1996 1995 1994
<S> <C> <C> <C>
Current-
Federal $ 67,000 $ 52,000 $--
State 3,000 -- --
Foreign 33,000 2,000 --
--------- -------- ---
103,000 54,000 --
Deferred-
Federal (67,000) (52,000) --
Charge in lieu of income taxes -- 148,000 --
--------- -------- ---
$ 36,000 $150,000 $--
========= ======== ===
</TABLE>
<TABLE>
A reconciliation of the federal statutory rate to the Company's effective
tax rate for the three years ended June 30, 1996 is as follows:
<CAPTION>
1996 1995 1994
<S> <C> <C> <C>
Income tax provision at federal statutory rate 34.0% 34.0% 34.0%
Increase (decrease) in tax resulting from--
Utilization of operating loss carryforwards -- (3.1) --
Operating loss carryforwards not benefited -- -- 14.0
Temporary items with no tax benefit 7.3 -- (49.5)
Tax credits utilized (4.1) (6.4) --
Change in valuation allowance (35.5) (7.1) --
Prior year tax adjustments 5.0 -- --
Other 1.5 3.1 1.5
----- ----- -----
Effective tax rate 8.2% 20.5% --%
===== ===== =====
</TABLE>
25
<PAGE> 44
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 1996
(Continued)
(6) INCOME TAXES (Continued)
<TABLE>
The components of the net deferred tax asset at June 30, 1996 and 1995 are
approximately as follows:
<CAPTION>
1996 1995
<S> <C> <C>
Reserves and accruals not yet deducted for tax
purposes $175,000 $ 265,000
Other temporary differences 17,000 17,000
-------- ---------
192,000 282,000
Valuation allowance (73,000) (230,000)
-------- ---------
Net deferred tax asset $119,000 $ 52,000
======== =========
</TABLE>
A full valuation allowance was provided upon the adoption of SFAS No. 109
in 1993 due to the uncertainty at that time of the future realizability of
the Company's deferred tax asset. During fiscal 1996 and 1995, the Company
reduced the valuation allowance by $157,000 and $52,000, respectively,
which represents recognition of the portion of the deferred tax asset that
can be carried back to offset the prior years' tax liabilities, if
necessary.
(7) PROFIT SHARING PLAN
The Company has a defined contribution profit-sharing plan that covers all
eligible employees. The Company has accrued and expensed an employer
contribution to this plan of $50,000 in fiscal 1996 and $50,000 in fiscal
1995. No employer contributions were made in fiscal 1994.
26
<PAGE> 45
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
------------------------------------------------
ACCOUNTING AND FINANCIAL DISCLOSURE.
------------------------------------
None.
PART III
ITEM 9 DIRECTORS, EXECUTIVE OFFICERS, AND CONTROL PERSONS; Compliance with
Section 16(a) of the Exchange Act. The Company will furnish to the
Securities and Exchange Commission a definitive Proxy Statement (the
"Proxy Statement") not later than 120 days after the close of its
fiscal year ended June 30, 1996. The information required by this item
is incorporated herein by reference to the Proxy Statement.
ITEM 10 EXECUTIVE COMPENSATION. The information required by this item is
incorporated herein by reference to the Proxy Statement.
ITEM 11 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT. The
information required by this item is incorporated herein by reference
to the Proxy Statement.
ITEM 12 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS. The information
required by this item is incorporated herein by reference to the Proxy
Statement.
PART IV
ITEM 13 EXHIBITS AND REPORTS ON FORM 8-K.
---------------------------------
(a) Exhibits.
---------
The exhibits listed below are filed with or incorporated by reference in
this report.
3.1 Articles of Organization of the Company(1)
3.2 By-laws of Precision Optics Corporation, Inc.(2)
4.1 Specimen common stock certificate(1)
4.2 Private Placement Selling Agent Common Stock Warrant No. 4 dated
April 28, 1992 issued to James L. Davis and Schedule 1 of Omitted
Documents(3)
4.3 Initial Public Offering Common Stock Purchase Warrant No. 3 dated
July 10, 1992 issued to John C. Michalak and Schedule 2 of
Omitted Documents(3)
4.4 Warrant No. U-1 to Purchase Shares of Common Stock of the Company
dated January 24, 1992 issued to Nathan Newman and Schedule 3 of
Omitted Documents(3)
4.5 Promissory Note dated December 5, 1991 between the Company and
The First National Bank of Boston.(4)
4.6 Agreement Restricting Sale of Stock dated January 15, 1992 by and
among Richard E. Forkey, the Company, Kennedy, Mathews, Landis,
Healy & Pecora Incorporated, and Equity Securities Trading Co.,
Inc.(3)
27
<PAGE> 46
4.7 Option Share Escrow Agreement by and among the Company, the
Commissioner of Commerce for the State of Minnesota, Resource
Bank & Trust, and David McNally and Schedule of Omitted
Documents(4)
10.1 Lease dated June 29, 1984 between the Company and Equity, First
Amendment to Commercial Lease dated June 25, 1990, and letter
agreement dated June 25, 1990 renewing such lease(1)
10.2 Precision Optics Corporation, Inc. 1989 Stock Option Plan amended
to date (the "Plan")(5)
10.3 Stock Option to Joel R. Pitlor dated May 30, 1989 and letter
agreement dated June 25, 1990 amending such option(1)
10.4 Stock Option to Robert R. Shannon dated June 25, 1990(2)
10.5 Stock Option to Joel R. Pitlor dated April 7, 1992 and Schedule 4
of Omitted Documents(3)
10.6 Form of the Company's Non-disclosure and Non-Competition
Agreement(1)
10.7 Three separate life insurance policies on the life of Richard E.
Forkey(1)
10.8 Agreement dated October 19, 1991 between the Boston Stock
Exchange and the Company(2)
10.9 Agreement dated November 18, 1991 between The NASDAQ Stock Market
and the Company(3)
10.10 Master Lease Finance Agreement dated November 3, 1993 between the
Company and BancBoston Leasing.(5)
10.11 Second Amendment to Commercial Lease between the Company and
Equity dated December 9, 1994.
10.12 Lease dated November 1, 1995 between the Company and Janice M.
Bouchard, Trustee of Authority Drive Realty Trust.
21 Subsidiaries of Precision Optics Corporation, Inc.
99 Important Factors Regarding Forward-Looking Statements.(6)
1 Incorporated herein by reference to the Company's Registration Statement on
Form S-18 (No. 33-36710-B).
2 Incorporated herein by reference to the Company's 1991 Annual Report on
Form 10-KSB.
3 Incorporated herein by reference to the Company's 1992 Annual Report on
Form 10-KSB.
4 Incorporated herein by reference to the Company's Registration Statement on
Form S-1 (No.33-43929).
5 Incorporated herein by reference to the Company's 1994 Annual Report on
Form 10-KSB.
6 Incorporated herein by reference to the Company's Quarterly Report on Form
10-QSB for the quarter ended March 31, 1996.
(b) Reports on Form 8-K.
-------------------
None.
28
<PAGE> 47
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: September 19, 1996 PRECISION OPTICS CORPORATION, INC.
By:/s/ Richard E. Forkey
-------------------------
Richard E. Forkey
Chairman of the Board and
Chief Executive Officer
In accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.
By:/s/ Richard E. Forkey By:/s/ Jack P. Dreimiller
----------------------------- -------------------------------
Richard E. Forkey Jack P. Dreimiller
President, Treasurer, and Senior Vice President, Finance
Director (Principal and Chief Financial Officer
Executive Officer) (Principal Financial and
Accounting Officer)
September 19, 1996 September 19, 1996
- -------------------------------- ------------------
Date Date
By:/s/ Joel R. Pitlor By:/s/ Edward A. Benjamin
----------------------------- -------------------------------
Joel R. Pitlor Edward A. Benjamin
Director Director
September 19, 1996 September 19, 1996
- -------------------------------- ------------------
Date Date
By:/s/ Robert R. Shannon
-----------------------------
Robert R. Shannon
Director
September 19, 1996
- --------------------------------
Date
29
<PAGE> 48
INDEX TO EXHIBITS
3.1 Articles of Organization of the Company(1)
3.2 By-laws of Precision Optics Corporation, Inc.(2)
4.1 Specimen common stock certificate(1)
4.2 Private Placement Selling Agent Common Stock Warrant No. 4 dated
April 28, 1992 issued to James L. Davis and Schedule 1 of Omitted
Documents(3)
4.3 Initial Public Offering Common Stock Purchase Warrant No. 3 dated
July 10, 1992 issued to John C. Michalak and Schedule 2 of
Omitted Documents(3)
4.4 Warrant No. U-1 to Purchase Shares of Common Stock of the Company
dated January 24, 1992 issued to Nathan Newman and Schedule 3 of
Omitted Documents(3)
4.5 Promissory Note dated December 5, 1991 between the Company and
The First National Bank of Boston.(4)
4.6 Agreement Restricting Sale of Stock dated January 15, 1992 by and
among Richard E. Forkey, the Company, Kennedy, Mathews, Landis,
Healy & Pecora Incorporated, and Equity Securities Trading Co.,
Inc.(3)
4.7 Option Share Escrow Agreement by and among the Company, the
Commissioner of Commerce for the State of Minnesota, Resource
Bank & Trust, and David McNally and Schedule of Omitted
Documents(4)
10.1 Lease dated June 29, 1984 between the Company and Equity, First
Amendment to Commercial Lease dated June 25, 1990, and letter
agreement dated June 25, 1990 renewing such lease(1)
10.2 Precision Optics Corporation, Inc. 1989 Stock Option Plan amended
to date (the "Plan")(5)
10.3 Stock Option to Joel R. Pitlor dated May 30, 1989 and letter
agreement dated June 25, 1990 amending such option(1)
10.4 Stock Option to Robert R. Shannon dated June 25, 1990(2)
10.5 Stock Option to Joel R. Pitlor dated April 7, 1992 and Schedule 4
of Omitted Documents(3)
10.6 Form of the Company's Non-disclosure and Non-Competition
Agreement(1)
10.7 Three separate life insurance policies on the life of Richard E.
Forkey(1)
10.8 Agreement dated October 19, 1991 between the Boston Stock
Exchange and the Company(2)
10.9 Agreement dated November 15, 1991 between The NASDAQ Stock Market
and the Company(3)
10.10 Master Lease Finance Agreement dated November 3, 1993 between the
Company and BancBoston Leasing.(5)
10.11 Second Amendment to Commercial Lease between the Company and
Equity dated December 9, 1994.
10.12 Lease dated November 1, 1995 between the Company and Janice M.
Bouchard, Trustee of Authority Drive Realty Trust.
21 Subsidiaries of Precision Optics Corporation, Inc.
99 Important Factors Regarding Forward-Looking Statements.(6)
1 Incorporated herein by reference to the Company's Registration Statement on
Form S-18 (No. 33-36710-B).
2 Incorporated herein by reference to the Company's 1991 Annual Report on
Form 10-KSB.
3 Incorporated herein by reference to the Company's 1992 Annual Report on
Form 10-KSB.
4 Incorporated herein by reference to the Company's Registration Statement on
Form S-1 (No.33-43929).
30
<PAGE> 49
5 Incorporated herein by reference to the Company's 1994 Annual Report on
Form 10-KSB.
6 Incorporated herein by reference to the Company's Quarterly Report on Form
10-QSB for the quarter ended March 31, 1996.
31
<PAGE> 50
[Graphic of rectangle]
Your
Partner
with a
Vision
[Graphic of sign]
poc inc.
PRECISION OPTICS CORPORATION
22 East Broadway. Gardner, MA 01440
508-630-1800 1-800-447-2812 Fax 508-630-1487
